RECRUITINGINTERVENTIONAL
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure
About This Trial
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with autonomic failure and with supine hypertension from all races
Who Should NOT Join This Trial:
- All medical students
- Pregnant women
- High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)
- History of serious allergies or asthma.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with autonomic failure and with supine hypertension from all races
Exclusion Criteria:
* All medical students
* Pregnant women
* High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction)
* History of serious allergies or asthma.
Treatments Being Tested
DEVICE
continuous positive airway pressure (CPAP)
Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
DRUG
Placebo
Placebo pill or patch. Single dose
Locations (1)
Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Nashville, Tennessee, United States